Drug Profile


Alternative Names: ASP 4130; AV-951; Kil8951; KRN-951; Tivopath

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AVEO Oncology; Institute Gustave-Roussy; Kyowa Hakko Kirin
  • Class Antineoplastics; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Renal cell carcinoma
  • Phase I Solid tumours
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 09 Feb 2017 EUSA Pharma receives Day 180 List of Outstanding Issues from CHMP for tivozanib
  • 28 Nov 2016 EUSA Pharma has submits responses to the EMA Day 120 List of Questions, issued by the CHMP as part of the MAA for tivozanib
  • 08 Nov 2016 Ophthotech announces intention to submit IND to the US FDA for Macular degeneration in the first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top